Top pedigree leading Xcovery’s kinase inhibitors
With two leading biotech entrepreneurs and scientists at the helm, closely held Xcovery Holdings has a leg up as it continues development of next generation kinase inhibitors as treatments for cancer...
View ArticleLeerink starts Marati at outperform
Leerink Swann has initiated coverage of Mirati Therapeutics (NASDAQ:MRTX) with an “outperform” rating and price target of $25. The share are changing hands at $17.38 on Monday morning. Mirati is an...
View ArticleRoth starts Argos Therapeutics at buy
Roth Capital Partners has initiated coverage of Argos Therapeutics (NASDAQ:ARGS) with a “buy” rating and $21 price target, saying the company has the potential to be one of the leaders in cancer...
View Article
More Pages to Explore .....